Beamion PANTUMOR-1: A Study to Test Whether Zongertinib Helps People With Advanced Cancers With HER2 Alterations

ClinicalTrials.gov ID: NCT06581432

Public ClinicalTrials.gov record NCT06581432. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 6, 2026, 2:16 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Beamion PANTUMOR-1: A Phase II, Multicentre, Multicohort, Open-label Trial to Evaluate the Efficacy and Safety of Oral Zongertinib (BI 1810631) for the Treatment of Selected HER2-mutated or Overexpressed/Amplified Solid Tumours

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a study for people with advanced cancer for whom previous treatment was not successful. Adults aged 18 and over with advanced cancer with HER2 alterations can join the study. The purpose of this study is to find out whether a medicine called zongertinib helps people with advanced cancers with HER2 alterations. HER2 alterations can cause cancer. Zongertinib inhibits HER2. Participants are put into groups based on the type of advanced cancer they have, the type of HER2 alterations they have, and the dose of zongertinib they receive. Depending on the group they are in, participants take 1 of 2 different doses of zongertinib each day. Participants can continue the treatment as long as they benefit from it and can tolerate it. Participants visit the study site regularly. During many of the visits, the doctors check the size of the tumour and whether it has spread to other parts of the body. During all the visits, the doctors check participants' health and take note of any unwanted effects.

Study identification

NCT ID: NCT06581432
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 2
Lead sponsor: Boehringer Ingelheim; Industry
Enrollment: 588 participants

Conditions and interventions

Conditions

Solid Tumours

Interventions

Zongertinib Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Oct 10, 2024
Primary completion: Nov 29, 2028
Completion: Dec 28, 2028
Last update posted: Sep 1, 2026

2024 – 2028

United States locations

U.S. sites: 20
U.S. states: 15
U.S. cities: 19

Facility	City	State	ZIP	Site status
Alaska Oncology and Hematology, LLC	Anchorage	Alaska	99508	Recruiting
University of Arizona Comprehensive Cancer Center	Tucson	Arizona	85719	Completed
Precision NextGen Oncology	Beverly Hills	California	90212	Recruiting
Scripps Cancer Center Torrey Pines	La Jolla	California	92037	Recruiting
Valkyrie Clinical Trials	Los Angeles	California	90067	Recruiting
Yale University School of Medicine	New Haven	Connecticut	06511	Recruiting
BRCR Global	Tamarac	Florida	33321	Recruiting
Illinois Cancer Specialists	Arlington Heights	Illinois	60005	Recruiting
Community MD Anderson Cancer Center - East Medical Oncology	Indianapolis	Indiana	46219	Recruiting
Maryland Oncology Hematology, Columbia	Columbia	Maryland	21044	Recruiting
Karmanos Cancer Institute	Detroit	Michigan	48201	Completed
Presbyterian Healthcare Services	Albuquerque	New Mexico	87110	Recruiting
Icahn School of Medicine at Mount Sinai	New York	New York	10029	Recruiting
Memorial Sloan-Kettering Cancer Center	New York	New York	10065	Recruiting
Taylor Cancer Research Center	Maumee	Ohio	43537	Recruiting
Alliance Cancer Specialists, PC, Wynnewood	Wynnewood	Pennsylvania	19096	Recruiting
Sarah Cannon Research Institute at Mary Crowley	Dallas	Texas	75230	Recruiting
The University of Texas MD Anderson Cancer Center	Houston	Texas	77030	Recruiting
Texas Oncology - Plano West	Plano	Texas	75093	Recruiting
Virginia Cancer Specialists, PC	Fairfax	Virginia	22031	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 72 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT06581432, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Sep 1, 2026 · Synced Sep 6, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06581432 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →